Efficient amplification of melanoma-specific CD8+ T cells using artificial antigen presenting complex

Area of Science:

• Immunology
• Cancer Therapy
• Cellular Biology

Background:

• Adoptive cell transfer (ACT) therapy shows promise for treating cancers unresponsive to immunization.
• Generating sufficient tumor-specific cytotoxic T lymphocytes (CTLs) via autologous antigen presenting cells (APCs) is a significant challenge in ACT.
• Tumor-specific CTLs are crucial for effective anti-tumor immune responses.

Purpose of the Study:

• To develop and evaluate artificial antigen presenting cells (aAPCs) for enhanced in vitro amplification of tumor-specific CTLs.
• To compare the efficacy of aAPCs with natural splenic APCs in stimulating and expanding antigen-specific T cells.
• To establish a more efficient method for generating large numbers of CTLs for ACT immunotherapy.

Main Methods:

• Development of aAPCs using MHC class I molecules loaded with a melanoma-specific TRP-2 peptide epitope.
• In vitro stimulation and amplification of T cells using aAPCs and natural splenic APCs.
• Assessment of CTL recognition of tumor cells and validation with ovalbumin peptide-loaded aAPCs and OT-I TCR transgenic cells.

Main Results:

• aAPCs demonstrated superior in vitro stimulation and amplification of TRP-2-specific CD8+ T cells compared to natural splenic APCs.
• aAPC-induced CTLs effectively recognized endogenously processed antigens on B16F10 melanoma cells.
• Prior in vivo immunization followed by aAPC expansion ('prime and expand') simplified CTL amplification.

Conclusions:

• aAPCs are a highly effective tool for the large-scale in vitro amplification of rare tumor-specific CTLs.
• The 'prime and expand' regimen using aAPCs offers a viable alternative for enhancing CTLs in ACT immunotherapy.
• aAPCs represent a significant advancement for improving the efficacy of adoptive cell transfer in cancer treatment.